Immune-based Therapies
Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma
Cancer Research Communications 2024 January 3 [Link] Jitendra Badhai, Nick Landman, Gaurav Kumar Pandey, Ji-Ying Song, Danielle Hulsman, Oscar Krijgsman, Gayathri Chandrasekaran, Anton Berns, Maarten van Lohuizen Abstract Malignant mesothelioma is a highly aggressive tumor with a survival of only 4-18 months after diagnosis. Treatment options for this disease are limited. Immune checkpoint blockade using…
Read MoreSalvage pleurectomy/decortication following immunotherapy for malignant pleural mesothelioma
Interdisciplinary Cardiovascular and Thoracic Surgery 2023 November 15 [Link] Masaru Takenaka, Koji Kuroda, Katsuma Yoshimatsu, Masataka Mori, Masatoshi Kanayama, Akihiro Taira, Taiji Kuwata, Fumihiro Tanaka Abstract Salvage surgery following immunotherapy is a promising treatment option for advanced malignant tumour. However, only a few cases of salvage surgery for malignant pleural mesothelioma (MPM) have been reported.…
Read MoreDevelopment of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Nature Communications 2023 November 3 [Link] Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, Mikko Mäyränpää, Jukka Partanen, Satu Koskela, Jarno Honkanen, Jussi Halonen, Lukasz Kuryk, Maria Rescigno, Mikaela Grönholm, Rui M Branca, Janne Lehtiö, Vincenzo Cerullo…
Read MoreCo-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
AME Case Reports 2023 August 3 [Link] Mindan Wu, Zhixuan Li, Junfu Cai, Xianyang Zhong, Wenchuan Zheng, Shuhan Wu, Maohuang Lin, Qichuan Zhang Abstract Background: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line…
Read MorePleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement
Expert Opinion on Therapeutic Targets 2023 October 30 [Link] Jean-Baptiste Assié, Didier Jean Abstract Introduction: Pleural mesothelioma is a rare and aggressive cancer originating in the pleura, with a devastating prognosis and limited treatment options. There have been significant advancements in the management of this disease in recent years. Since 2021, nivolumab and ipilimumab immune…
Read MoreFunctional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor
Cancer Immunology, Immunotherapy 2023 October 18 [Link] Derrick McCarthy, Michael Lofgren, Amy Watt, Holly Horton, Philippe Kieffer-Kwon, Jian Ding, Sebastian Kobold, Patrick A Baeuerle, Robert Hofmeister, Dario A Gutierrez, Robert Tighe Abstract T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC®), called TC-210, have demonstrated robust antitumor activity in preclinical models of…
Read MoreComprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma
Medicine 2023 October 13 [Link] Jiren Weng, Jing Chen Abstract To explore the influence and effect of tumor microenvironment on the development of malignant mesothelioma using machine learning methods. 87 open cases were downloaded from the Cancer Genome Atlas database including transcriptome data, clinical data, and mutation data. The immune, stromal, and estimate scores were…
Read MoreBrain Metastases With Malignant Peritoneal Mesothelioma: Never Reported Before
Cureus 2023 August 19 [Link] Darshan Lal, Merissa Misiura, Waqas Adeel, Rizwan Tariq Abstract Malignant mesothelioma is a very rare diagnosis. Malignant mesotheliomas arise from surface linings of pleura, peritoneal cavity, or tunica vaginalis and pericardium with pleural malignant mesotheliomas being the most common. The incidence of brain metastases has been very low with malignant…
Read MoreKrebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Lung Cancer 2023 September 7 [Link] Paul Stockhammer, Hannah Baumeister, Till Ploenes, Francesco Bonella, Dirk Theegarten, Balazs Dome, Christine Pirker, Walter Berger, Luca Hegedüs, Marcell Baranyi, Martin Schuler, Sophie Deshayes, Servet Bölükbas, Clemens Aigner, Christophe Blanquart, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare disease with dismal outcome. Systemic treatment options include chemotherapy…
Read MoreZimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2023 August 6 [Link] Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He, Qi Deng Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage, and the standard first-line treatment for inoperable patients is chemotherapy. Although combining programmed cell death 1 (PD-1) inhibitors with chemotherapy is…
Read More